Disclosed herein are peptide sequences capable of directing adeno-associated viruses (AAV) to target specific environments, for example the nervous system and the heart, in a subject. Also disclosed are AAVs having non-naturally occurring capsid proteins comprising the disclosed peptide sequences, and methods of using the AAVs to treat diseases.

Thioctamer, a nanoconjugate of glatiramer acetate (GA) and thioctic acid (TA), e.g. in the form of nanospheres, is provided as are compositions comprising thioctamer and methods of using the same for wound healing. Application of thioctamer to a wound accelerates wound healing, compared to control wounds that are not treated with the copolymer.

Thioctamer, a nanoconjugate of glatiramer acetate (GA) and thioctic acid (TA), e.g. in the form of nanospheres, is provided as are compositions comprising thioctamer and methods of using the same for wound healing. Application of thioctamer to a wound accelerates wound healing, compared to control wounds that are not treated with the copolymer.

Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The α-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.

Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The α-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.

The present invention relates to inhibitors of the interaction between H. pylori HopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based on H. pylori HopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with H. pylori.

An antimicrobial agent comprising a selenium nanoparticle (SeNP) core and one or more superficially located antimicrobial peptide/s (AMP). The or each AMP may comprise an excess of positively charged amino acids compared to negatively charged amino acids and the AMP may comprise peptides from classes selected from polylysine, such as ε-poly-L-lysine (ε-PL), polyarginine, aurein, ovispirin, melittin, magainin, cecropin, andropin, moricin, ceratotoxin, melittin, magainin, dermaseptin, bombinin, brevinin, esculentins, buforin, cathelicidin, abaecin, apidaecin, prophenin and indolicidin. Products comprising such agents, methods of producing the agents and methods of killing or retarding growth of microorganisms exposed to the agents are also disclosed.

An antimicrobial agent comprising a selenium nanoparticle (SeNP) core and one or more superficially located antimicrobial peptide/s (AMP). The or each AMP may comprise an excess of positively charged amino acids compared to negatively charged amino acids and the AMP may comprise peptides from classes selected from polylysine, such as ε-poly-L-lysine (ε-PL), polyarginine, aurein, ovispirin, melittin, magainin, cecropin, andropin, moricin, ceratotoxin, melittin, magainin, dermaseptin, bombinin, brevinin, esculentins, buforin, cathelicidin, abaecin, apidaecin, prophenin and indolicidin. Products comprising such agents, methods of producing the agents and methods of killing or retarding growth of microorganisms exposed to the agents are also disclosed.

An antimicrobial agent comprising a selenium nanoparticle (SeNP) core and one or more superficially located antimicrobial peptide/s (AMP). The or each AMP may comprise an excess of positively charged amino acids compared to negatively charged amino acids and the AMP may comprise peptides from classes selected from polylysine, such as ε-poly-L-lysine (ε-PL), polyarginine, aurein, ovispirin, melittin, magainin, cecropin, andropin, moricin, ceratotoxin, melittin, magainin, dermaseptin, bombinin, brevinin, esculentins, buforin, cathelicidin, abaecin, apidaecin, prophenin and indolicidin. Products comprising such agents, methods of producing the agents and methods of killing or retarding growth of microorganisms exposed to the agents are also disclosed.

The present invention relates to inhibitors of the interaction between H. pylori IIopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based on H. pylori HopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with H. pylori.